MAPK8 and fatty liver disease: Mechanistically, USP18 mitigates hepatic steatosis by interacting with and deubiquitinating TGFβ‐activated kinase 1 (TAK1), thereby inhibiting its activation and consequently suppressing the downstream JNK and NF‐κB signalling pathways [20].